Evaluation of PROMIS Measures After Radical Prostatectomy
In a study reported in the Journal of Clinical Oncology, Agochukwu et al validated the sexual interest and sexual satisfaction single-item measures of the Patient-Reported Outcome Measurement Information System (PROMIS) in men who underwent radical prostatectomy for prostate cancer.
The study involved 1,604 patients who underwent robotic radical prostatectomy between May 2014 and January 2016 in the Michigan Urological Surgery Improvement Collaborative. Convergent and discriminant validity of the PROMIS sexual interest and sexual satisfaction measures were assessed using Spearman correlation coefficients.
Validity and Performance of Measures
The findings generally supported convergent and discriminant validity of the two PROMIS measures. The PROMIS T scores for satisfaction and interest had moderate to large correlations with scores for other measures of sexual satisfaction and interest, supporting convergent validity, and had little or no correlation with measures of dissimilar cognitive construct (eg, bowel function and general quality of life), supporting discriminant validity.
The mean PROMIS sexual interest item T score decreased significantly from baseline to 3 months (P = .001) and increased significantly from 3 months to 24 months (P < .001), with the 24-month scores being higher than baseline scores (P < .001). The mean PROMIS sexual satisfaction T score decreased from baseline to 3 months (P < .001) and increased from 3 months to 24 months (P = .002) but did not return to baseline levels.
The investigators concluded, “PROMIS Global Satisfaction With Sex Life and Interest in Sexual Activity single-item measures are fundamental measures in prostate cancer survivorship. Patients are interested in sex despite functional losses and can salvage satisfaction, thereby giving insight into attainable patient-centered survivorship goals for sexual recovery after radical prostatectomy.”
Nnenaya Q. Agochukwu, MD, of the Department of Urology, University of Michigan, Ann Arbor, is the corresponding author for the Journal of Clinical Oncology article.
Disclosure: The study was supported by a grant from the National Institutes of Health. For full disclosures of the study authors, visit jco.ascopubs.org.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
